Terms: = Lymphoma AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
15 results:
1. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
Kondo N; Utsumi T; Shimizu Y; Takemoto A; Oh-Hara T; Uchibori K; Subat-Motoshi S; Ninomiya H; Takeuchi K; Nishio M; Miyazaki Y; Katayama R
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917191
[TBL] [Abstract] [Full Text] [Related]
2. Role of Advanced MR Imaging in Diagnosis of Neurological Malignancies: Current Status and Future Perspective.
Eraky AM; Beck RT; Treffy RW; Aaronson DM; Hedayat H
J Integr Neurosci; 2023 May; 22(3):73. PubMed ID: 37258452
[TBL] [Abstract] [Full Text] [Related]
3. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance.
Usman RM; Razzaq F; Akbar A; Farooqui AA; Iftikhar A; Latif A; Hassan H; Zhao J; Carew JS; Nawrocki ST; Anwer F
Asia Pac J Clin Oncol; 2021 Jun; 17(3):193-208. PubMed ID: 32970929
[TBL] [Abstract] [Full Text] [Related]
4. Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.
Leng S; Moshier E; Tremblay D; Hu L; Biran N; Barman N; Parekh S; Cho H; Madduri D; Richter J; Barlogie B; Jagannath S; Chari A
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e734-e751. PubMed ID: 32660906
[TBL] [Abstract] [Full Text] [Related]
5. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G; Mezquita L; Facchinetti F; Planchard D; Gazzah A; Bigot L; Rizvi AZ; Frias RL; Thiery JP; Scoazec JY; Sourisseau T; Howarth K; Deas O; Samofalova D; Galissant J; Tesson P; Braye F; Naltet C; Lavaud P; Mahjoubi L; Abou Lovergne A; Vassal G; Bahleda R; Hollebecque A; Nicotra C; Ngo-Camus M; Michiels S; Lacroix L; Richon C; Auger N; De Baere T; Tselikas L; Solary E; Angevin E; Eggermont AM; Andre F; Massard C; Olaussen KA; Soria JC; Besse B; Friboulet L
Clin Cancer Res; 2020 Jan; 26(1):242-255. PubMed ID: 31585938
[TBL] [Abstract] [Full Text] [Related]
6. Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS.
Attwa MW; Darwish HW; Alhazmi HA; Kadi AA
Clin Chim Acta; 2018 Oct; 485():298-304. PubMed ID: 30006284
[TBL] [Abstract] [Full Text] [Related]
7. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract] [Full Text] [Related]
8. 15α-methoxypuupehenol Induces Antitumor Effects
Hilliard TS; Miklossy G; Chock C; Yue P; Williams P; Turkson J
Mol Cancer Ther; 2017 Apr; 16(4):601-613. PubMed ID: 28069875
[TBL] [Abstract] [Full Text] [Related]
9. Subclinical Hypothyroidism in Childhood Cancer Survivors.
Lee HJ; Hahn SM; Jin SL; Shin YJ; Kim SH; Lee YS; Kim HS; Lyu CJ; Han JW
Yonsei Med J; 2016 Jul; 57(4):915-22. PubMed ID: 27189285
[TBL] [Abstract] [Full Text] [Related]
10. Proteomic-based identification of multiple pathways underlying n-butylidenephthalide-induced apoptosis in LNCaP human prostate cancer cells.
Pang CY; Chiu SC; Harn HJ; Zhai WJ; Lin SZ; Yang HH
Food Chem Toxicol; 2013 Sep; 59():281-8. PubMed ID: 23770345
[TBL] [Abstract] [Full Text] [Related]
11. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
van Besien K; Stock W; Rich E; Odenike O; Godley LA; O'Donnell PH; Kline J; Nguyen V; Del Cerro P; Larson RA; Artz AS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):913-21. PubMed ID: 22079470
[TBL] [Abstract] [Full Text] [Related]
12. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia.
Kawamata N; Ogawa S; Seeger K; Kirschner-Schwabe R; Huynh T; Chen J; Megrabian N; Harbott J; Zimmermann M; Henze G; Schrappe M; Bartram CR; Koeffler HP
Int J Oncol; 2009 Jun; 34(6):1603-12. PubMed ID: 19424578
[TBL] [Abstract] [Full Text] [Related]
13. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.
Lipton JH; Khoroshko N; Golenkov A; Abdulkadyrov K; Nair K; Raghunadharao D; Brummendorf T; Yoo K; Bergstrom B;
Leuk Lymphoma; 2007 Mar; 48(3):497-505. PubMed ID: 17454589
[TBL] [Abstract] [Full Text] [Related]
14. From morphological to molecular diagnosis of soft tissue tumors.
Miettinen M
Adv Exp Med Biol; 2006; 587():99-113. PubMed ID: 17163160
[TBL] [Abstract] [Full Text] [Related]
15. The risk of radiation-induced cancer in patients with squamous cell carcinoma of the head and neck and its results of treatment.
Amemiya K; Shibuya H; Yoshimura R; Okada N
Br J Radiol; 2005 Nov; 78(935):1028-33. PubMed ID: 16249604
[TBL] [Abstract] [Full Text] [Related]
